Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the discussion. On CapEx, the company plans for potential greenfield or brownfield expansion around FY28-29 with estimated costs of about INR 50 crore. CapEx for the current year is limited to R&D Center-related expenses only. The company focuses on internal growth, R&D investments, and capacity utilization without indicating external fundraising. Board considerations such as buybacks are probabilistic and not confirmed, with no concrete plans announced.

Any current/future capex/capital investment/strategic investment?

No major CapEx planned for the current fiscal year except for R&D-related investments. Upcoming R&D Center in Nashik targeted to be operational by the end of Q2 of the coming year. Initial focus of the new R&D Center will be on strain development, protein engineering, and fermentation. Larger CapEx of about INR 50 crore anticipated around FY28-29 for greenfield or brownfield expansion. Continued efforts to invest in R&D and new product pipelines to support growth and market expansion. Strategic investments linked to evolving market opportunities such as healthcare, biochemical processing, and

Future growth expectations in sales/revenue/volumes?

The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22). Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22). There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24). Stronger inquiries and interest are seen particularly in the U.S. marketplace, focusing on enzymes and probiotics segments (Pages 17, 19). The company aims to expand into new geographical and application m

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years. Growth will be uneven ("roller coaster"), with some years faster and some slower. EBITDA margins may face tariff impacts, but current outlook suggests a worst-case 1% impact (vs. earlier 2%), with efforts to pass costs to customers to mitigate margin pressure. Profit before tax and profit after tax have shown increases in recent quarters, reflecting improving financials. Expansion of product pipelines, including enzymes, probiotics, biocatalysis, and biopharma areas, is expe

Current/ Expected Orderbook/ Pending Orders?

Multiple products are currently under trial with various customers, but specific timelines for outcomes are uncertain; updates expected by Q1 of the next financial year. The company is continuously monitoring several pipeline products; some progress quickly while others take longer due to pilot scale and market acceptance processes. There is a strong focus on expanding market inquiries, especially in the U.S. for enzymes and probiotics segments, indicating growing interest and potential orders. No explicit details on the exact size or value of the current order book or pending orders wer

IN US

Sale is live|00:00:00left today

Advanced Enzyme Technologies LtdQ4 FY27Pharmaceuticals & Biotechnology

Advanced Enzyme Technologies Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹374P/E: 25.4Market Cap: ₹4.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→The company expects steady growth of 13% to 15% CAGR over the next 3 to 5 years, with some variability year-to-year (Page 22).
→Growth will not be linear; some years may see faster expansion while others slower, reflecting a roller coaster trend (Page 22).
→There are multiple products under trial and development, with outcomes expected by the first quarter of the next financial year (Page 24).
→Stronger inquiries and interest are seen particularly in the U.S. marketplace, focusing on enzymes and probiotics segments (Pages 17, 19).
→The company aims to expand into new geographical and application markets, especially in healthcare and biochemical processing, to utilize capacity and grow revenues (Page 17).
→U.S. sales volumes are expected to pick up within the current financial year, aided by improved tariff conditions and increased inquiries (Pages 19, 21).
→R&D and new product launches will support sustained growth (Pages 17, 19).

Margin guidance

Category 3

→The company expects a medium to long-term overall revenue growth of 13% to 15% annually over the next 3-5 years.
→Growth will be uneven ("roller coaster"), with some years faster and some slower.
→EBITDA margins may face tariff impacts, but current outlook suggests a worst-case 1% impact (vs. earlier 2%), with efforts to pass costs to customers to mitigate margin pressure.
→Profit before tax and profit after tax have shown increases in recent quarters, reflecting improving financials.
→Expansion of product pipelines, including enzymes, probiotics, biocatalysis, and biopharma areas, is expected to drive future top-line growth.
→New R&D centers and innovations are expected to support growth in new applications and market areas, especially healthcare and biochemical processing.
→U.S. market performance is critical and improving, aided by lower tariffs and strategic customer management, which should enhance earnings going forward.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the discussion.
→On CapEx, the company plans for potential greenfield or brownfield expansion around FY28-29 with estimated costs of about INR 50 crore.
→CapEx for the current year is limited to R&D Center-related expenses only.
→The company focuses on internal growth, R&D investments, and capacity utilization without indicating external fundraising.
→Board considerations such as buybacks are probabilistic and not confirmed, with no concrete plans announced.

Order book

→Multiple products are currently under trial with various customers, but specific timelines for outcomes are uncertain; updates expected by Q1 of the next financial year.
→The company is continuously monitoring several pipeline products; some progress quickly while others take longer due to pilot scale and market acceptance processes.
→There is a strong focus on expanding market inquiries, especially in the U.S. for enzymes and probiotics segments, indicating growing interest and potential orders.
→No explicit details on the exact size or value of the current order book or pending orders were provided in the call.
→Management emphasizes a pipeline-driven approach rather than reliance on single-product orders, aiming for steady revenue generation as products mature.
→The outlook includes increased inquiries and interest reflecting a healthier order flow expected in the near to medium term.

Capex plans

Yes

→No major CapEx planned for the current fiscal year except for R&D-related investments.
→Upcoming R&D Center in Nashik targeted to be operational by the end of Q2 of the coming year.
→Initial focus of the new R&D Center will be on strain development, protein engineering, and fermentation.
→Larger CapEx of about INR 50 crore anticipated around FY28-29 for greenfield or brownfield expansion.
→Continued efforts to invest in R&D and new product pipelines to support growth and market expansion.
→Strategic investments linked to evolving market opportunities such as healthcare, biochemical processing, and industrial enzymes.

How does Advanced Enzyme Technologies Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Advanced Enzyme Technologies Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Advanced Enzyme Technologies Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio